<code id='DBD5152159'></code><style id='DBD5152159'></style>
    • <acronym id='DBD5152159'></acronym>
      <center id='DBD5152159'><center id='DBD5152159'><tfoot id='DBD5152159'></tfoot></center><abbr id='DBD5152159'><dir id='DBD5152159'><tfoot id='DBD5152159'></tfoot><noframes id='DBD5152159'>

    • <optgroup id='DBD5152159'><strike id='DBD5152159'><sup id='DBD5152159'></sup></strike><code id='DBD5152159'></code></optgroup>
        1. <b id='DBD5152159'><label id='DBD5152159'><select id='DBD5152159'><dt id='DBD5152159'><span id='DBD5152159'></span></dt></select></label></b><u id='DBD5152159'></u>
          <i id='DBD5152159'><strike id='DBD5152159'><tt id='DBD5152159'><pre id='DBD5152159'></pre></tt></strike></i>

          entertainment

          entertainment

          author:focus    Page View:99
          A scientist working at SQZ Biotechnologies in Watertown's Arsenal Yards. -- biotech coverage from STAT
          A scientist working at SQZ Biotechnologies in Watertown, Mass. David L Ryan/Globe Staff

          Next stop: Beacon Hill.

          Governor Maura Healey’s long-awaited plan to double down on state funding for the biotech and medical technology sector came into focus Thursday with the announcement she’ll seek $1 billion over the next decade to reauthorize the state’s 16-year-old life sciences initiative.

          advertisement

          But lawmakers so far are noncommittal on funding the plan. The proposal — dubbed “Life Sciences 3.0″ — is part of a larger economic development bill the Healey administration is expected to file soon. Several expressed support for an industry in which Massachusetts is a leader, but also noted the spending request comes at a time of competing priorities.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          After affirmative action ruling, medical educators look to 'holistic review'
          After affirmative action ruling, medical educators look to 'holistic review'

          AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s

          read more
          Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead
          Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

          HasPhRMAlostitsfangs?Are11th-hourchangesominousforclinicaltrials?Andwhat’snextinpainmedicine?Wecover

          read more
          Jerome Adams on the need for new antivirals for Covid
          Jerome Adams on the need for new antivirals for Covid

          PaxlovidtabletsamplesbeinginspectedinFreiburg,Germany.PfizerviaAPTheU.S.Covid-19Public HealthEmergen

          read more

          As AI regulations shape up, health tech startups beg for clarity

          AdobeThefederalgovernment’splantoboostitsoversightoftheuseofartificialintelligencetoolsinhealthcared